Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...